Lineage B.1.351

Sixth Wave Detects UK and South African Variants of SARS-CoV-2

Thursday, June 10, 2021 - 12:00pm

The virus variants detected include the UK variant and the South African variant.

Key Points: 
  • The virus variants detected include the UK variant and the South African variant.
  • There are documented cases of new variants circumventing the human immune system and causing reinfection and drastically reduced efficacy of certain vaccines.
  • Sixth Wave continues to expand the capabilities of the AMIP diagnostic platform as it works on improving the specificity and sensitivity in their prototype devices.
  • Sixth Wave can design, develop and commercialize MIP solutions across a broad spectrum of industries.

New Study Published in Nature Provides Further Evidence that COVID-19 Vaccine Induced T-Cell Response Targets Known SARS-CoV-2 Variants of Concern

Wednesday, June 9, 2021 - 12:15pm

The study provides further evidence that the T-cell response may contribute to protection from COVID-19.

Key Points: 
  • The study provides further evidence that the T-cell response may contribute to protection from COVID-19.
  • In the multinational phase 3 ENSEMBLE trial, participants given Johnson & Johnsons vaccine experienced similar efficacy against the B.1.351 variant.
  • Mapping exactly how the variants impact different parts of the virus can indicate if the immune response is likely to be affected.
  • The tool can be used to study the T-cell immune response for vaccine research across COVID-19 variants., mapping across >160KSARS-CoV-2-specific antigen-TCR sequence-level data.

Eurofins Launches a New Multiplex PCR Assay for Rapid Detection of the B.1.617 “India” SARS-CoV-2 Variant

Thursday, June 3, 2021 - 6:15am

Eurofins Technologies (Paris:ERF) announces the launch of its GSD NovaType III SARS-CoV-2 RT-PCR assay, developed for the rapid detection of SARS-CoV-2 Variants of Concern including B.1.617 (India), B.1.427/B.1.429 (California/USA), B.1.351 (South Africa) or P.1 (Brazil).

Key Points: 
  • Eurofins Technologies (Paris:ERF) announces the launch of its GSD NovaType III SARS-CoV-2 RT-PCR assay, developed for the rapid detection of SARS-CoV-2 Variants of Concern including B.1.617 (India), B.1.427/B.1.429 (California/USA), B.1.351 (South Africa) or P.1 (Brazil).
  • The assay facilitates the identification of the relevant mutations E484Q, E484K and L452R in one reaction combined with the simultaneous discrimination from the S gene E484 wildtype variant.
  • These mutations have been associated with reports of potential decreased efficacy of certain vaccines and an increase in the transmissibility of the virus.
  • Eurofins Technologies is committed to continue to rapidly adapt its product offering to the meet the evolving challenges of SARS-CoV-2.

Scripps Research Institute testing shows Viraleze highly active against UK COVID strain

Tuesday, June 1, 2021 - 10:03am

Starpharma is alsotesting the Japan/Brazil and South African variants of COVID, with the results expected in the coming weeks.

Key Points: 
  • Starpharma is alsotesting the Japan/Brazil and South African variants of COVID, with the results expected in the coming weeks.
  • The antiviral testing was conducted by the renowned Scripps Research Institute in the US, with the UK variant of SARS-CoV-2, which has been classified as a variant of concern.
  • The UK variant was recently reported to be responsible for over 98% of the positive COVID infections in England and linked to multiple outbreaks worldwide.
  • Viraleze is registered for sale in Europe and the UK, and is available through one of the UK's largest pharmacy chains, LloydsPharmacy.

Clover Announces Positive Preclinical Data for Second-Generation Protein-Based COVID-19 Vaccine Candidate Demonstrating Broad Neutralization Against Variants of Concern

Tuesday, May 18, 2021 - 4:39am

B.1.351 S-Trimer demonstrated broad neutralization against the original SARS-CoV-2 strain and variants of concern, specifically the South African variant (B.1.351), Brazil variant (P.1), and UK variant (B.1.1.7).

Key Points: 
  • B.1.351 S-Trimer demonstrated broad neutralization against the original SARS-CoV-2 strain and variants of concern, specifically the South African variant (B.1.351), Brazil variant (P.1), and UK variant (B.1.1.7).
  • Clover is at the forefront of vaccine R&D utilizing our proprietary Trimer-Tag technology and is the first company to disclose preclinical data demonstrating that a modified protein-based COVID-19 vaccine candidate can potentially induce broad neutralization against the original SARS-CoV-2 strain and variants of concern," said Joshua Liang, Chief Executive Officer of Clover Biopharmaceuticals.
  • As the SARS-CoV-2 virus mutates and additional data emerges, we are prepared to innovate and develop next-generation COVID-19 vaccines.
  • Any forward-looking statement made by us in this document speaks only as of the date on which it is made.

DGAP-News: CureVac : Second-Generation COVID-19 Vaccine Candidate, CV2CoV, Demonstrates High Immunogenicity Against Virus Variants in Preclinical Study

Thursday, May 13, 2021 - 1:06pm

In addition, the serum of vaccinated animals showed significant cross-neutralization against variants first discovered in Denmark (B.1.1.298), the UK (B.1.1.7) and South Africa (B.1.351).

Key Points: 
  • In addition, the serum of vaccinated animals showed significant cross-neutralization against variants first discovered in Denmark (B.1.1.298), the UK (B.1.1.7) and South Africa (B.1.351).
  • "Spurred by the emergence of virus variants that have the potential to affect the efficacy of currently approved first-generation mRNA COVID-19 vaccines, CureVac and GSK aim to jointly develop second-generation vaccine candidates that offer improved immune responses and target emerging variants.
  • Combined with lower doses, these second-generation vaccines could enable also broad protection against selected strains in a multivalent vaccine format.
  • In December 2020, CureVac initiated a pivotal Phase 2b/3, the HERALD study, with a 12\xc2\xb5g dose of CVnCoV.

Moderna Announces New Supply Agreement with Switzerland for 7 Million Booster Vaccine Doses in 2022 and Option for Additional 7 Million Doses

Thursday, May 6, 2021 - 11:00am

Purchase under this agreement is subject to regulatory approval of the booster vaccine candidate.

Key Points: 
  • Purchase under this agreement is subject to regulatory approval of the booster vaccine candidate.
  • Today\xe2\x80\x99s announcement follows two earlier agreements between Switzerland and Moderna to supply a total of 13.5 million doses of the COVID-19 Vaccine Moderna.
  • A booster dose of mRNA-1273.351, the Company\xe2\x80\x99s strain-matched booster, achieved higher neutralizing antibody titers against the B.1.351 variant of concern than a booster dose of mRNA-1273.
  • On May 12, the U.S Food and Drug Administration granted the Moderna COVID-19 Vaccine Fast Track designation.

Moderna Announces Positive Initial Booster Data Against SARS-CoV-2 Variants of Concern

Wednesday, May 5, 2021 - 9:01pm

A booster dose of mRNA-1273.351, the Company\xe2\x80\x99s strain-matched booster, achieved higher neutralizing antibody titers against the B.1.351 variant of concern than a booster dose of mRNA-1273.

Key Points: 
  • A booster dose of mRNA-1273.351, the Company\xe2\x80\x99s strain-matched booster, achieved higher neutralizing antibody titers against the B.1.351 variant of concern than a booster dose of mRNA-1273.
  • We are encouraged by these new data, which reinforce our confidence that our booster strategy should be protective against these newly detected variants.
  • We look forward to sharing data on our multivalent booster candidate, mRNA-1273.211, which combines mRNA-1273 and mRNA-1273.351 in a single vaccine, when available.
  • Today\xe2\x80\x99s update includes preliminary data two weeks following administration of a booster dose of mRNA-1273 or mRNA-1273.351.